OncBioMune To Become Exclusive Distributor of Lipomed Drugs in Mexico

August 10th, 2017|0 Comments

BATON ROUGE, LA--(August 10, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]

OncBioMune Submits Application to Commercialize Anti-Rabies Drug in Mexico

August 3rd, 2017|0 Comments

BATON ROUGE, LA--(August 3, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]

OncBioMune Acquires Propolis Product Line from German Partner

July 20th, 2017|0 Comments

BATON ROUGE, LA--(July 20, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]

Phase 2 Trial of ProscaVax for Early-Stage Prostate Cancer Nears Commencement

July 13th, 2017|0 Comments

BATON ROUGE, LA--(July 13, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]

OncBioMune Pharmaceuticals Establishes Another Revenue Stream; Schedules First Patient with AAT Deficiency for Treatment in Mexico

June 28th, 2017|0 Comments

BATON ROUGE, LA--(June 28, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]

Enrollment to Begin in OncBioMune’s Trial of ProscaVax for Prostate Cancer in Mexico

June 27th, 2017|0 Comments

BATON ROUGE, LA—(June 27, 2017) – OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (“OncBioMune” or the “Company”), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]

OncBioMune Receives Patent Protecting Novel Cancer Vaccine in Mexico

June 21st, 2017|0 Comments

BATON ROUGE, LA—(June 21, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]

OncBioMune Awarded Patent for ProscaVax in Japan

June 20th, 2017|0 Comments

BATON ROUGE, LA--(June 20, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]

OncBioMune Acquires Norepinefrine for Low Blood Pressure and Heart Failure in Mexico from Teva Pharmaceuticals Mexico

June 19th, 2017|0 Comments

MEXICO CITY, MEXICO--(June 19, 2017) - OncBioMune México, S.A. De C.V., (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted [...]

OncBioMune, AqVida add additional drugs to distribution agreement (Paclitaxel and Oxaliplatin)

June 15th, 2017|0 Comments

BATON ROUGE, LA--(June 15, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune Protects ProscaVax Cancer Treatment Technology in Hong Kong

June 7th, 2017|0 Comments

BATON ROUGE, LA--(June 07, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies [...]

OncBioMune’s Andfrt(R) Shown in Clinical Trial to Improve Sperm Count and Mobility

June 6th, 2017|0 Comments

BATON ROUGE, LA--(June 06, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies [...]

Protocol Submitted to FDA for Phase 2 Clinical Trial of ProscaVax as Immunotherapy for Early-Stage Prostate Cancer

June 1st, 2017|0 Comments

BATON ROUGE, LA—(June 01, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of targeted cancer [...]

OncBioMune Reports Record Monthly Sales for Bekunis(R) in May

May 31st, 2017|0 Comments

BATON ROUGE, LA--(May 31, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of targeted cancer [...]

OncBioMune Receives Approval for Male Fertility Product in Mexico

May 30th, 2017|0 Comments

BATON ROUGE, LA--(May 30, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune CMO Begins Formulation Work on Tretinoin for Acute Promyelocytic Leukemia

May 23rd, 2017|0 Comments

BATON ROUGE, LA--(May 23, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune Provides Corporate Update, Nearly 50 Drug Candidates in Pipeline or Being Negotiated

May 9th, 2017|0 Comments

BATON ROUGE, LA--(May 9, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP)("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of targeted cancer therapies and [...]

OncBioMune Completes Enrollment in Phase 1 Trial of ProscaVax for Prostate Cancer

May 3rd, 2017|0 Comments

BATON ROUGE, LA--(May 03, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of targeted cancer [...]

OncBioMune, AqVida Partner for Commercializing Cancer and Other Generic Drugs in Mexico

April 26th, 2017|0 Comments

Companies Negotiating Joint Venture for Clinical Development of ProscaVax for Prostate Cancer in Europe BATON ROUGE, LA--(April 26, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or [...]

OncBioMune Licenses Tretinoin for the Treatment of Acute Promyelocytic Leukemia Throughout Mexico, Central and Latin America

April 20th, 2017|0 Comments

BATON ROUGE, LA--(April 20, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]